Unlocking the potential of
genomic medicine

2018 News Releases

Date Title
Toggle Summary08/14/2018
- Top Line Data for Part A expected in Q4 2018 PHILADELPHIA , Aug. 14, 2018 /PRNewswire/   -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) today announced that it has completed enrollment in Part A (n=64) of its Phase 2 ASCEND clinical trial, which is assessing a mGluR mutation positive
Toggle Summary08/02/2018
PHILADELPHIA , Aug. 2, 2018 /PRNewswire/ --  Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the "Company") announced today financial and operational results for the three months ended June 30 , 2018 and provided an overview of the Company's recent corporate progress.
Toggle Summary07/19/2018
-FDA provisionally agreed that AEVI-004 is a co-crystal and a novel drug substance -FDA provisionally agreed existing AEVI-001 toxicology and pathology studies are acceptable to support clinical development with AEVI-004, with minimal preclinical bridging studies -AEVI-004 is expected to have
Toggle Summary06/13/2018
PHILADELPHIA , June 13, 2018 /PRNewswire/ --  Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that Michael F. Cola , President and Chief Executive Officer, will present at the JMP Securities Life Sciences Conference on Wednesday, June 20, 2018 at 1:00 p.m. EDT at the St.
Toggle Summary06/12/2018
- Enrollment of ASCEND trial to be increased from 42 to 64 participants - Top-line results expected during the fourth quarter 2018 PHILADELPHIA , June 12, 2018 /PRNewswire/ --   Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) today announced that it will increase the sample size for Part A
Toggle Summary05/29/2018
PHILADELPHIA , May 29, 2018 /PRNewswire/ --  Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that Michael F. Cola , President and Chief Executive Officer, will present at the Jefferies 2018 Global Healthcare Conference on Thursday, June 7, 2018 at 4:30 p.m.
Toggle Summary05/15/2018
PHILADELPHIA , May 15, 2018 /PRNewswire/ --   Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the "Company") announced today financial and operational results for the three months ended March 31 , 2018 and provided an overview of the Company's recent corporate progress.
Toggle Summary03/20/2018
PHILADELPHIA , March 20, 2018 /PRNewswire/ --  Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that Michael F. Cola , President and Chief Executive Officer, will present at the 17th Annual Needham Healthcare Conference at 8:30 AM EDT on Wednesday, March 28, 2018 at the
Toggle Summary03/13/2018
PHILADELPHIA , March 13, 2018 /PRNewswire/ --  Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today financial and operational results for the three and twelve months ended December 31, 2017 . Fourth Quarter and Year-End Corporate Highlights Continued advancing and strengthening
Toggle Summary03/07/2018
-Early stage program in an ultra-orphan pediatric indication with potential to expand to additional indications post proof of concept. PHILADELPHIA , March 7, 2018 /PRNewswire/ --  Aevi Genomic Medicine, Inc. (NASDAQ MKT: GNMX) today announced that it has expanded its collaboration with Kyowa Hakko